Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?

Basit Öğe Kaydı
dc.contributor.authorUlaş, Arife
dc.contributor.authorAvcı, Nilüfer
dc.contributor.authorKöş, Fahriye Tuğba
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorBulut, Nilüfer
dc.contributor.authorDeğirmenci, Mustafa
dc.date.accessioned2020-04-30T22:39:37Z
dc.date.available2020-04-30T22:39:37Z
dc.date.issued2015
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000358399700006en_US
dc.descriptionPubMed: 26214622en_US
dc.description.abstractPurpose: To investigate whether the pretreatment neutrophil lymphocyte ratio (NLR) and the platelet lymphocyte ratio (PLR) have any prognostic significance in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab. Methods: 187 patients were retrospectively analyzed. The patients were separated into two groups according to the mean value of NLR and PLR (low NLR <= 2.38, high NLR >2.38; and low PLR <= 161.28, high PLR > 161.28, respectively). The relationship between pretreatment NLR, PLR and clinicopathological factors was investigated. Univari ate and multivariate Cox regression analyses were performed. To evaluate survival rates, the Kaplan-Meier method with log rank test were used. Results: The median duration of follow up was 26.0 months (range 6.0-84.0). In high NLR and PLR groups, the mean age was lower, tumor size was larger and the number of hormone receptor positive patients was higher. No statistically significant relationship was found between clinicopathological factors and both NLR and PLR groups. During follow up, the rate of relapse was 12.6% in the low NLR group, 16.2 % in the high NLR group, 12.6% in the low PLR group and 15.8% in the high PLR group (p=non significant). Although median disease free survival (DFS) was shorter in the high NLR than in the low NLR group, the difference was not statistically significant (p=0.45). No statistically significant difference was found between high and low PLR groups with regard to median DFS and overall survival (OS) (p=0.76, p=0.29, respectively). Conclusion: We conclude that in HER2-positive early breast cancer patients receiving adjuvant trastuzumab with high pretreatment NLR, DFS was shorter. As for PLR, no effect either on DFS or on OS was registered. Prospective studies with larger number of patients are required in order to evaluate the prognostic effect of NLR and PLR in HER2-positive breast cancer patients.en_US
dc.identifier.endpage722en_US
dc.identifier.issn1107-0625
dc.identifier.issue3en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage714en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12684/2781
dc.identifier.volume20en_US
dc.identifier.wosWOS:000358399700006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherZerbinis Medical Publen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbreast canceren_US
dc.subjectHER2 positiveen_US
dc.subjectlymphocytesen_US
dc.subjectneutrophilen_US
dc.subjectplateleten_US
dc.titleAre neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu